Silverback Therapeutics, Inc. (Nasdaq: SBTX) has announced that CEO Laura Shawver, Ph.D., will present at several upcoming virtual investor conferences. Key events include the Goldman Sachs West Coast Biotech Bus Tour on February 23, 2021, the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, the Cowen 41st Annual Healthcare Conference on March 3, 2021, and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Webcasts and replays of selected presentations will be available on Silverback's website for 30 days.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) has successfully closed its initial public offering of 13,225,000 shares at $21.00 per share, raising approximately $277.7 million in gross proceeds. The offering includes the full exercise of the underwriters' option to purchase additional shares. Shares began trading on December 4, 2020. Goldman Sachs & Co. LLC, SVB Leerink, and Stifel served as joint book-running managers, while H.C. Wainwright & Co. was the lead manager. Registration statements are effective as of December 3, 2020, and copies are available on the SEC's website.
Silverback Therapeutics announced the pricing of its initial public offering (IPO) of 11,500,000 shares at $21.00 each, aiming for gross proceeds of $241.5 million. The shares will list on Nasdaq under the symbol SBTX, starting December 4, 2020, with the offering expected to close on December 8, 2020. A 30-day option for underwriters to purchase an additional 1,725,000 shares at the IPO price has been included. Goldman Sachs, SVB Leerink, and Stifel serve as joint book-running managers for this offering.